MEF2C Protein

MEF2C Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">MEF2C Protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>MEF2C (Myocyte Enhancer Factor 2C)</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>MEF2C</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[Q06413](https://www.uniprot.org/uniprot/Q06413)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~51 kDa</td>
</tr>
<tr>
<td class="label">Amino Acids</td>
<td>473</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Nucleus</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>MADS-box transcription factor family</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain (cortex, hippocampus, basal ganglia, cerebellum), skeletal muscle, heart</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">HDAC inhibitors</td>
<td>Valproic acid, SAHA</td>
</tr>
<tr>
<td class="label">Calcineurin activators</td>
<td>Ophiocordyceps-derived compounds</td>
</tr>
<tr>
<td class="label">BDNF mimetics</td>
<td>Indirect MEF2C activation</td>
</tr>
<tr>
<td class="label">AAV-MEF2C</td>
<td>Gene therapy</td>
</tr>
<tr>
<td class="label">MEF2C transcriptional activators</td>
<td>Novel small molecules</td>
</tr>
<tr>
<td class="label">Application</td>
<td>Sample</td>
</tr>
<tr>
<td

MEF2C Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">MEF2C Protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>MEF2C (Myocyte Enhancer Factor 2C)</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>MEF2C</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[Q06413](https://www.uniprot.org/uniprot/Q06413)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~51 kDa</td>
</tr>
<tr>
<td class="label">Amino Acids</td>
<td>473</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Nucleus</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>MADS-box transcription factor family</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain (cortex, hippocampus, basal ganglia, cerebellum), skeletal muscle, heart</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">HDAC inhibitors</td>
<td>Valproic acid, SAHA</td>
</tr>
<tr>
<td class="label">Calcineurin activators</td>
<td>Ophiocordyceps-derived compounds</td>
</tr>
<tr>
<td class="label">BDNF mimetics</td>
<td>Indirect MEF2C activation</td>
</tr>
<tr>
<td class="label">AAV-MEF2C</td>
<td>Gene therapy</td>
</tr>
<tr>
<td class="label">MEF2C transcriptional activators</td>
<td>Novel small molecules</td>
</tr>
<tr>
<td class="label">Application</td>
<td>Sample</td>
</tr>
<tr>
<td class="label">AD risk stratification</td>
<td>Blood (eQTL)</td>
</tr>
<tr>
<td class="label">Disease progression</td>
<td>CSF</td>
</tr>
<tr>
<td class="label">Treatment response</td>
<td>Blood</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">Alzheimer's disease</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">88 edges</a></td>
</tr>
</table>

MEF2C (Myocyte Enhancer Factor 2C) is a calcium-dependent transcription factor belonging to the MADS-box family of MEF2 proteins. It is a critical regulator of neuronal gene expression, essential for synaptic plasticity, learning and memory, dendritic spine formation, and neuronal survival[@potthoff2007][@harrington2020]. MEF2C is also a genome-wide association study (GWAS)-identified risk gene for Alzheimer's disease, establishing it as a direct molecular link between genetic susceptibility and disease mechanisms[@lambert2013]. MEF2C dysfunction is increasingly recognized in both AD and PD, making it an important therapeutic target[@li2021][@kim2022].

Protein Information

Structure

Domain Architecture

MEF2C contains distinct functional domains[@potthoff2007]:

• MADS domain (1-56 aa): DNA binding, dimerization, interaction with co-repressors
• MEF2 domain (85-129 aa): Co-factor binding, specifies MEF2 family interactions
• Transactivation domain (125-450 aa): Recruits co-activators (p300/CBP, HDAC3)
• NLPB (N-terminal repressive) domain (55-100 aa): Mediates repression by class IIa HDACs
• Multiple phosphorylation sites: S396, T300, T320 — regulated by kinases

DNA Binding

MEF2C binds as a homodimer or heterodimer (with MEF2A, MEF2B, or MEF2D) to the consensus DNA sequence CTA(A/T)4TAG, known as the MEF2 site, found in promoters and enhancers of neuronal genes.

Normal Function

Calcium-Dependent Activation

MEF2C activity is tightly regulated by neuronal activity and calcium signaling[@mckinsey2002]:

Key Transcriptional Targets

MEF2C regulates genes essential for neuronal function[@harrington2020]:

• Synaptic proteins: Synapsin I/II (SYN1/2), PSD-95 (DLG4), CaMKIIδ (CAMK2D)
• Ion channels: Kv4.2 (KCND2), HCN1, Nav1.2 (SCN2A)
• Cytoskeletal proteins: MAP2, neurofilament proteins (NEFL)
• Survival factors: BDNF, Bcl-2 (BCL2), Mcl-1 (MCL1)
• Differentiation: MyoD (muscle), neuronal-specific transcription factors

Synaptic Plasticity

MEF2C is a master regulator of activity-dependent synaptic remodeling[@harrington2020]:

• LTP consolidation: MEF2C is required for long-term potentiation in hippocampal neurons
• Synapse elimination: MEF2C promotes elimination of unused synapses during development
• Memory formation: MEF2C deletion causes deficits in contextual fear conditioning and spatial memory
• Experience-dependent plasticity: Sensory experience activates MEF2C in vivo

Role in Alzheimer's Disease

MEF2C as an AD Risk Gene

A landmark GWAS meta-analysis identified MEF2C as a susceptibility locus for AD[@lambert2013]:

• rs6733839: The index SNP is located near MEF2C on chromosome 5q14.3
• Population-specific effects: Risk allele frequencies vary across ancestral groups
• Functional impact: Risk variant affects MEF2C expression in brain tissue
• Pathway enrichment: MEF2C-dependent gene networks are enriched in AD brains

MEF2C Dysregulation in AD

In AD brain tissue, MEF2C is consistently altered[@li2021]:

• Reduced MEF2C expression: Decreased mRNA and protein in AD hippocampus and cortex
• Correlation with pathology: Lower MEF2C levels correlate with higher amyloid burden and NFT density
• Synaptic dysfunction: Loss of MEF2C contributes to synaptic failure and memory impairment

Mechanisms of Dysfunction

Neuroprotection by MEF2C

MEF2C provides neuroprotection through multiple pathways:

• Synaptic protein regulation: Maintains expression of PSD-95, synapsin, and NMDA receptor subunits
• Anti-apoptotic gene expression: Bcl-2 and other survival factors
• BDNF regulation: MEF2C directly activates BDNF transcription
• Inflammatory modulation: MEF2C suppresses neuroinflammatory gene programs

Therapeutic Implications

• MEF2C activators: Small molecules that enhance MEF2C activity
• HDAC inhibitors: Trichostatin A and valproic acid increase MEF2C expression
• Calcineurin activation: Enhancing calcium-dependent MEF2C activation
• AAV-MEF2C: Gene therapy vectors for MEF2C delivery

Role in Parkinson's Disease

Neuroprotection in Dopaminergic Neurons

MEF2C plays important roles in the survival of dopaminergic neurons[@kim2022]:

• Neuroprotective signaling: MEF2C activation protects against 6-OHDA and MPTP toxicity
• TH regulation: MEF2C can regulate tyrosine hydroxylase expression
• Synaptic maintenance: Supports synaptic connectivity in nigrostriatal circuits

LRRK2-MEF2C Interactions

Pathogenic LRRK2 mutations affect MEF2C regulatory pathways[@kim2022]:

• LRRK2 G2019S: Increases MEF2C phosphorylation at inhibitory sites, reducing activity
• Dopaminergic vulnerability: Reduced MEF2C activity contributes to LRRK2-mediated toxicity
• Therapeutic potential: Restoring MEF2C function may counteract LRRK2 pathogenic effects

MEF2C in PD Models

• MPTP model: MEF2C expression is altered in substantia nigra after MPTP
• Alpha-synuclein models: MEF2C activity is suppressed by alpha-synuclein pathology
• Neurotrophin signaling: MEF2C mediates some effects of GDNF and BDNF in dopaminergic neurons

Animal Models

MEF2C Knockout

• Lethal phenotype: Germline knockout causes embryonic lethality (E9.5) due to cardiac defects
• Conditional neuronal knockout: Survives to adulthood with impairments:
• Impaired synaptic plasticity (reduced LTP)
• Spatial memory deficits
• Altered dendritic spine morphology
• Increased seizure susceptibility

Overexpression Models

• Synaptic protection: MEF2C overexpression protects against excitotoxicity and Aβ toxicity
• Memory enhancement: Transgenic MEF2C overexpression enhances object recognition and spatial memory
• Neuroprotection: MEF2C overexpression in AD models reduces amyloid-induced synaptic loss

GWAS Validation

MEF2C AD risk SNPs functionally alter MEF2C expression:

• Human brain tissue: Risk allele correlates with reduced MEF2C mRNA
• iPSC neurons: Risk allele carriers show altered neuronal development
• Mouse models: Partial MEF2C knockdown recapitulates AD-like synaptic deficits

Therapeutic Strategies

Biomarkers

Cross-Links

• [MEF2C Gene](/genes/mef2c)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Synaptic Plasticity Mechanisms](/mechanisms/synaptic-plasticity)
• [Calcium Signaling in Neurodegeneration](/mechanisms/calcium-dysregulation-neurodegeneration)
• [Transcription Factor Pathways](/mechanisms/transcription-factor-pathways)

See Also

• [MEF2A Protein](/proteins/mef2a-protein) — related family member
• [CREB1 Protein](/proteins/creb1-protein) — related calcium-dependent TF
• [BDNF Protein](/proteins/bdnf-protein) — MEF2C transcriptional target
• [HDAC Enzymes](/entities/hdac-enzymes) — MEF2C repressors
• [LRRK2 Protein](/proteins/lrrk2-protein) — interacts with MEF2C in PD

References